Rapid diagnostics test for detecting Chagas disease - Breaking barriers to diagnosis access in remote areas

Mendicino, Diego

doi:10.15761/cmid.1000158

Cited by 1 publication

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While national-level screening programs may exist in antenatal/perinatal settings, blood banks, and some hospital settings such as organ transplantation, we are unaware of coordinated systematic population screening across endemic regions, which could support multinational trial participation. Most patients are diagnosed in the stages of chronic indeterminate disease (CID) or having developed chronic determinate disease (CDD) with Widening the availability and use of immunochromatographic rapid diagnostic tests [53] in endemic regions may be a useful and pragmatic approach to improved study subject screening. Furthermore, the increasing trend toward decentralizing studies and use of remote technologies [54] may facilitate participation of patients in more remote regions, especially for screening and follow-up visits.…”

Section: Trial Methodology Considerationsmentioning

confidence: 99%

New Therapeutics for Chagas Disease: Charting a Course to Drug Approval

Man¹,

Segal²

2022

Chagas Disease - From Cellular and Molecular Aspects of Trypanosoma Cruzi-Host Interactions to the Clinical Intervention

View full text Add to dashboard Cite

Little progress has been made since the 1960s and 1970s to widen the therapeutic arsenal against Trypanosoma cruzi, the causative pathogen of Chagas disease, which remains a frustrating and perplexing infectious disease. This chapter focuses on the strategic and operational challenges in the clinical drug development of a novel antitrypanosomal agent for Chagas disease. The various elements that contribute to a robust assessment of treatment effect including dose selection, choice of patient population, trial methodology, endpoint measures, and regulatory perspectives are discussed. The learnings herein should serve as resource to help researchers and other stakeholders optimize their clinical development plans and speed delivery of new medicines to patients with Chagas disease.

show abstract

Section: Trial Methodology Considerationsmentioning

confidence: 99%